Author:
Koren John,Miyata Yoshinari,Kiray Janine,O'Leary John C.,Nguyen Lana,Guo Jianping,Blair Laura J.,Li Xiokai,Jinwal Umesh K.,Cheng Jin Q.,Gestwicki Jason E.,Dickey Chad A.
Publisher
Public Library of Science (PLoS)
Reference27 articles.
1. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.;K Koya;Cancer Res,1996
2. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.;CD Britten;Clin Cancer Res,2000
3. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours.;DJ Propper;Ann Oncol,1999
4. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.;R Wadhwa;Cancer Res,2000
5. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member.;R Wadhwa;J Biol Chem,1998
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献